



Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium

REDWOOD CITY, Calif., Dec 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center. Four of the studies analyze *Oncotype DX*(R), the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

Following are details for each embargoed session (all times are in Central Standard Time):

-- Thursday, December 10, 2009, 5:30 p.m. - 7:30 p.m.

Abstract #112

Poster discussion (Poster Discussion 1 and Reception): "Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene Recurrence Score (RS) assay in node-positive, ER-positive breast cancer - An update of SWOG-8814 (INT0100)"

Presenter: Kathy S. Albain, M.D., Professor, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.

Location: Ballroom A

-- Friday, December 11, 2009, 7 a.m. - 9 a.m.

Abstract: #2031

Poster presentation (Poster Session II): "Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer"

Presenter: Ruth Oratz, M.D., NYU School of Medicine, New York, NY

Location: Exhibit Halls A-B

-- Saturday, December 12, 2009, 5:30 p.m. - 7:30 p.m.

Abstract: #5165

Poster presentation (Poster Session V): "Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways"

Presenter: Joseph Sparano, M.D., principal investigator for the Eastern Cooperative Oncology Group (ECOG) and director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center in New York, NY

Location: Exhibit Halls A-B

-- Sunday, December 13, 2009, 7 a.m. - 8:30 a.m.

Abstract: #6004

Poster presentation (Poster Session VI): "HER2 amplification, Polysomy Status and Breast Cancer Survival in a Large Kaiser Permanente Case-Control Study: Assessment of HER2 by Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Fluorescence in Situ Hybridization (FISH)"

Presenter: Rick Baehner, M.D., director of pathology at Genomic Health, Inc., and director of the Immunohistochemistry Core Laboratory at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco

Location: Exhibit Halls A-B

-- Sunday, December 13, 2009, 7 a.m. - 8:30 a.m.

Abstract: #6021

Poster presentation (Poster Session VI): "Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR"

Presenter: Joseph Anderson, M.D., pathologist at Genomic Health, Inc.

Location: Exhibit Halls A-B

About Oncotype DX(R)

The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer test has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in *The New England Journal of Medicine* and a chemotherapy benefit study published in *the Journal of Clinical Oncology*. As of November 2009, more than 8,000 physicians have ordered more than 120,000 tests in over 50 countries, and both Medicare and private health plans covering over 90 percent of U.S. insured lives, provide reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX(R) breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in the first quarter of 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health

<http://www.genomichealth.com>

Copyright (C) 2009 PR Newswire. All rights reserved